HIV

A new drug candidate developed by scientists from more than a dozen research institutions may function as an effective HIV-1 vaccine.

Multiple strains of HIV recombine into new variant.

Researchers develop method to identify drug resistance mutations in viremic and suppressed patients.

Patients with hepatitis C benefit from a collaborative approach that involves specialty pharmacists and other care providers working with patients to promote patient engagement, adherence to therapy, and management of comorbidities.

In 2014, the FDA approved notable new therapies for the treatment of cancer, bleeding disorders, inflammatory conditions, cystic fibrosis, pulmonary fibrosis, HIV, hepatitis C, multiple sclerosis, angioedema, and other conditions.

As costly new specialty medications come to market, the role of the payer in controlling formularies is becoming increasingly apparent.

Antiretroviral therapy has led to remarkable improvements in HIV-infected individuals. By suppressing HIV RNA to

Genomic sequencing reveals effect of hepatitis on genetic mutations in tumors.

Entry of web site into particular market correlates with increase in new cases.

The roles that community pharmacists play in human immunodeficiency virus prevention, testing and care are explored in several research and experience articles in the Journal of the American Pharmacists Association. The four articles discuss community pharmacists' roles and pharmacists' perceptions of their patient care services among people living with HIV.

More than 6000 HIV cases in the United States annually can be traced to Craigslist's personals ad sections.

Pharmacists can help limit negative treatment outcomes among patients with HIV.

Daily fixed-dose combination tablet contains 800 mg of darunavir and 150 mg of cobicistat.

Once-daily pill proven to suppress HIV through 48 weeks.

The FDA has approved Janssen Therapeutics' darunavir and cobicistat (Prezcobix) for the treatment of human immunodeficiency virus (HIV-1) in combination with other antiretroviral agents for adults with no darunavir resistance-associated substitutions.

The FDA today approved Bristol-Myers Squibb Company's atazanavir and cobicistat for the treatment of HIV-1 infection in adults in combination with other antiretroviral agents.

Pharmacist collaboration with physicians during a national shortage of intravenous trimethoprim/sulfamethoxazole may have helped mitigate negative treatment outcomes among HIV-infected patients with Pneumocystis jirovecii pneumonia.

Improved care for HIV-infected patients within the Kaiser Permanente system has essentially reversed their previously reported increased heart attack risk.

Although retail pharmacists in California are permitted to sell nonprescription syringes under legislative efforts to prevent HIV transmission among injection drug users (IDUs), recent research uncovered that many pharmacies still limit syringe access.

HIV-positive patients who live in the Deep South have lower survival rates compared with their counterparts residing across the rest of the nation.

mscripts and Avella Specialty Pharmacy have recently completed analyzing data demonstrating the effectiveness of mobile pharmacy apps in helping HIV patients better manage their disease through improved medication adherence. Results from this analysis show that HIV patients using a mobile app which provides refill reminders, dosage reminders and other prescription management functionality are 2.9 times more likely to be adherent.

Nine state region found to have lowest survival rates nationwide.

Decrease attributed to less toxic therapies and risk reduction measures.

Study warns there is no testing to support a net clinical benefit.

Study finds only a moderate increase in relative risk.

Thirty-eight of 40 hepatitis C patients treated with 3-drug combination cured in a recent trial.